On the heels of a unanimous FDA panel recommendation in March for an expanded indication of Boston Scientific's (Natick, Massachusetts) cardiac resynchronization therapy defibrillators (CRT-Ds), including the Cognis CRT-D for asymptomatic and mild heart failure patients, a new sub-analysis of the MADIT-CRT trial has shown that women with mild heart disease who had a CRT-D implanted had a 70% reduction in heart failure alone and a 72% reduction in death from any cause. (Medical Device Daily) Read More
